Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway.

Atherosclerosis - 1 Jul 2017

Tang Zhi-Han, Peng Juan, Ren Zhong, Yang Jing, Li Ting-Ting, Li Tao-Hua, Wang Zuo, Wei Dang-Heng, Liu Lu-Shan, Zheng Xi-Long, Jiang Zhi-Sheng

Abstract excerpt

BACKGROUND AND AIMS: Proprotein convertase subtilisin/kexin 9 (PCSK9) has emerged as a popular target in the development of new cholesterol-lowering drugs and therapeutic interventions for atherosclerosis. PCSK9 could accelerate atherosclerosis through mechanisms beyond the degradation of the hepatic low-density lipoprotein receptor. Several clinical studies suggested that PCSK9 is involved in atherosclerotic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aorta
Share to Aortic Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lipoproteins, LDL

Share to Mice, Knockout, ApoE

Share to Plaque, Atherosclerotic

Share to Proprotein Convertase 9

Share to RAW 264.7 Cells

Share to Toll-Like Receptor 4

Source

Identifiers

PMID: 28535426
DOI: 10.1016/j.atherosclerosis.2017.04.023

Genes

PCSK9
TLR4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway.PMID 28535426Read ↗

Proprotein Convertase Subtilisin/kexin Type 9 Links Inflammation to Vascular Endothelial Cell DysfunctionSemantic proximity Read ↗

PCSK9 with a gain of function D374Y mutation aggravates atherosclerosis by inhibiting PPARα expressionSemantic proximity Read ↗

Physiology and role of PCSK9 in vascular disease: Potential impact of localized PCSK9 in vascular wall.Semantic proximity Read ↗

PCSK9 promotes vascular neointimal hyperplasia through non-lipid regulation of vascular smooth muscle cell proliferation, migration, and autophagySemantic proximity Read ↗

Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.Semantic proximity Read ↗

Silencing hepatic PCSK9 via novel chimeric AAV8 mitigates the progression of atherosclerosis by inhibiting inflammation in ApoE−/− miceSemantic proximity Read ↗

PCSK9: a key modulator of cardiovascular health.Semantic proximity Read ↗

The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.Semantic proximity Read ↗

The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications.Semantic proximity Read ↗

Unravelling the functional significance of PCSK9.Semantic proximity Read ↗

Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015).Semantic proximity Read ↗

Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.